ArticlePDF Available


Obesity has reached epidemic proportions in this country. In an effort to address this major public health problem, people have adopted a variety of strategies. These include medical and surgical interventions, both rational and fad diets, exercise and assorted weight-loss dietary supplements. Recent U.S. Food & Drug Administration (FDA) action involving some of these proprietary supplements raises questions of both their safety and efficacy. This article reviews the evidence behind the components of many of these supplements and discusses the role of nutrition in weight loss.
Obesity has increased rapidly in the United States, and
almost 65 percent of the general population is overweight
or obese. An even higher prevalence occurs among minority
subpopulations. It is the most common form of malnutrition
in the U.S. In the period of 2003-2006, 11.3 percent of
children and adolescents aged 2 to 19 years were at or above
the 97th percentile of the BMI for age growth charts, and
31.9 percent were at or above the 85th percentile.1
The health and cost implications of obesity are enormous.
Both overweight and obesity are implicated in the incidence
of a number of diseases, including pre-diabetes, type 2
diabetes, metabolic syndrome, cardiovascular disease,
hypertension, stroke, dyslipidemia, gout, osteoarthritis,
complications of pregnancy, polycystic ovarian syndrome
and some cancers. The association of morbidity with over-
weight and obesity is not clear but has been demonstrated
in several studies.2-4 Financial implications related to the
treatment of disease associated with overweight and obesity
is overwhelming. Public and private health care costs for
overweight and obesity accounts for 5.5 to 7 percent of
national health expenditures in the United States.5
Body weight is determined primarily by the ratio of energy
intake to energy output. If caloric consumption is higher
than caloric expenditure, weight gain ensues; conversely, if
either consumption decreases or expenditure increase,
weight loss will be seen.
A number of different nutritional approaches have been
employed in efforts to lose weight. These strategies fall into
three broad categories: (1) limiting the total caloric intake
(i.e., low-calorie diets), (2) altering the specific quality
but not directly the quantity – of constituent dietary com-
ponents (e.g. low-carbohydrate diets, low-fat diets and the
like), and (3) use of dietary supplement additions to the
customary diet. While recognizing that rarely are any of
these strategies employed in isolation, the focus of this
article is the latter strategy.
Weight-loss Supplementation
The allure of a pill, whether pharmaceutical or nutriceutical,
which can allow one to shed pounds without making sacri-
fices at the dinner table, is irresistible. The quest for such an
agent drives the search for bariatric medications as well as
the burgeoning supplement industry. Over one-third of
adults report using a weight loss supplement at least once in
their life,6with nearly one in 10 having done so in the past
year.7These supplements may be purchased in pharmacies,
supermarkets, discount stores, gas stations and via mail
order, the Internet or direct-marketing sales.
The proposed mechanisms of supplements’ actions include
appetite suppression, metabolism boosting (e.g., “fat-burners”),
and inhibition of nutrient absorption (e.g., “fat- or carb-
blockers”). In spite of the plethora of formulations
available, there is little quantifiable evidence of safety or
efficacy for the top 10 most common ingredients.8
To date, there is no good evidence for any herbal appetite
suppressants. Garcinia cambogia (hydroxycitric acid) is
June 2010
Obesity has reached epidemic proportions in this country. In an effort to address this major public health problem,
people have adopted a variety of strategies. These include medical and surgical interventions, both rational and fad
diets, exercise and assorted weight-loss dietary supplements. Recent U.S. Food & Drug Administration (FDA)
action involving some of these proprietary supplements raises questions of both their safety and efficacy. This
article reviews the evidence behind the components of many of these supplements and discusses the role of
nutrition in weight loss.
Weight-loss Supplements: What is the Evidence?
B y M a rk K. Hu n t i ng t o n, MD , P h D, FAA F P;
R o ge r A . S he w m a ke , P h D , L N
often marketed as an appetite suppressant but has not
demonstrated efficacy.9Studies of another agent similarly
marketed, chromium, show some benefit in the control of
diabetes, but this efficacy does not extend to weight loss.10
Phenylpropanolamine, a stimulant with appetite-suppressing
effects, was withdrawn from the market due to its
association with hemorrhagic stroke.
Eighty percent of supplements used contain naturally
occurring stimulants.7While there is evidence that some,
such as a combination of caffeine and ephedra,11 are
effective in helping with weight loss, the data suggests that
others (e.g., phenylephrine12) are not. Efficacy is only part
of the picture, however. “Natural” is not synonymous with
“safe,” and adverse reactions or toxicities are possible with
supplement use. Ephedra and other stimulants may be
arrhythmogenic.13Bitter orange (Citrus aurantium), a
supplement containing stimulant synephrin alkaloids,
shows promise for weight loss14 but has been associated with
ischemic colitis15 and angina.16 Usnic acid, which uncouples
oxidative phosphorylation, may be hepatotoxic,17as is
Garcinia cambogia, the subject of recent FDA action.18
These situations highlight the need to balance benefit with
risk, and the importance of having reliable data upon which
to base such risk management decisions.
Some of the absorption blocking supplements appear to
offer benefit for weight loss. For example, users of Phaseolus
vulgaris (bean) extract, which interferes with carbohydrate
absorption, lost more weight than those taking a placebo in
one small study.19 Phytosterols inhibit fat absorption and
lead to weight loss in animal studies, though no human
weight-loss data are currently available.20
Fiber has been hypothesized to aid in weight loss in two
ways: by increasing a sense of satiety with the fiber’s mass
displacing that of calorie-rich dietary components and by
decreasing absorption through increased gastrointestinal
motility. Empirically, fiber’s effect varies, with insoluble
fiber demonstrating efficacy in weight loss,21 while soluble
fiber22 and chitosan23 do not.
There has been the suggestion that increasing dietary calci-
um intake may aid in weight loss. This is based in part on
retrospective observational studies showing that increased
dairy consumption correlates with decreased weight.24
However, meta-analyses of randomized controlled trials fail
to find an effect of either calcium or dairy products on total
amount or rate of weight loss.25 Vitamin D supplementation
does not result in weight loss, either.26
Linoleic acid supplementation does not result in weight loss
but has been suggested to promote fat distribution to a
theoretically more healthy body habitus.27 However, other
studies suggest it does not do this and worsens endothelial
function, possibly increasing risk for cardiovascular morbidity.28
Assorted other supplements such as pyruvate, medium-
chain triglycerides, fiber and DHEA have been looked at in
small studies over short terms but have also shown inconsis-
tent results in regard to their value as weight-loss aids.
Partial meal replacement with supplements appears to work
in a number of studies,29-32 though it isn’t clear whether it is
the action of the supplements or simply the elimination of
the caloric content of the replaced meal that is responsible
for the effects seen.
In spite of the uncertain value of dietary supplements in the
promotion of weight loss, there is good news. An associa-
tion was seen between the use of supplements and both
lower initial body mass index and slower age-associated
weight gain.33 Additionally, those who use vitamin supple-
ments as a part of their weight-loss program are also more
likely to have an adequate intake of essential nutrients
when compared to those who do not take supplements.34
The bottom line on dietary weight-loss supplements is that,
while there is clearly potential, few have been adequately
studied and none can be definitively recommended at this
time.35There is a critical need for quality studies of the
potential role for supplements in weight loss.
Dietary Supplementation
Apart from weight-loss purposes, is dietary supplementation
wise? Many individuals do not meet recommended levels of
nutrient intake due to dietary and other lifestyle choices. As
a result, dietary supplementation may be advised. A good
example of this is vitamin D in northern climates, especially
among those with more deeply pigmented skin. There are
several recommendations for taking supplements that can
be made: Avoid mega-doses and choose supplements that
provide 100 percent of the daily value (DV)36 of all the
vitamins unless there is a diagnosed deficiency. The label
should state “United States Pharmacopeia (USP)” indicat-
ing the amount of nutrients listed is accurate and that it will
dissolve within 60 minutes. Many supplements now have
added herbs, enzymes or amino acids that may interfere
with medications such as anticoagulants and should be used
with close monitoring of therapeutic levels.
Overuse of multivitamin and mineral supplements is of
concern.37,38 There is a possibility that excessive vitamin A
can increase the risk of hip fractures,39 and excessive iron
intake could aggravate hemochromatosis.40 Other concerns
include vitamin B12 deficiency being masked by large
intakes of folate.41 Supplementation of single nutrients
sometimes can have adverse effects on the absorption and
utilization of other nutrients and medications. Beta
carotene, vitamin A and vitamin E may increase mortality.42-45
If calcium supplementation is needed, an additional
calcium supplement should be taken in addition to the low
amount that is in multivitamin and mineral supplements.
Supplementation as an Adjunct to Other Weight-loss Strategies
There are important nutritional considerations for patients
who pursue other strategies beyond mere dietary modifica-
tion for weight management. This includes those who
pursue pharmacological, surgical or exercise-based strategies.
A vitamin/mineral supplement that does not exceed 100
percent DV may be helpful if an individual is implementing
these weight-loss plans.
Surgical weight loss
Bariatric surgery is a well established technique to help
attain weight loss. Malnutrition is a risk associated with
surgery in general and especially with bariatric surgery.
Specific nutrient deficiencies are associated with both
restrictive and malabsorptive surgery. Preoperative and
postoperative nutritional education coupled with patient
compliance can alleviate many of the nutritional deficien-
cies and concerns of these surgeries.
The considerable decline in food consumption, changes in
appetite, and decreases in absorption lead to nutritional
deficiencies. Nutrients most likely to be consumed in lower
amounts and/or have lower absorption include vitamin
B12, folate, iron, thiamine (vitamin B1), calcium, vitamin
A, vitamin D, vitamin E and vitamin K. Macronutrient
concerns also exist for protein.46-48 Nutrition education can
help the patient select more nutrient-dense foods and
utilize appropriate supplements to avoid most deficiencies.
It has also has been shown to reduce food intolerances,
regurgitation and to increase the ability to tolerate a wider
range of solid foods. Post-surgery education in regard to diet
advancement schedules is also necessary.49
Pharmacological weight loss aids
The use of medications such as orlistat (Xenicaltand
Allit) inhibits gastric and pancreatic lipase production and
decrease fat absorption. Orlistat has been shown to help
minimize weight regain after weight loss and is well tolerated
overall.50 Anal leakage, diarrhea, fatty stools, soft stools,
increased bowel movements and flatulence may occur,
especially if higher-fat diets are consumed. Patients need to
be taught about fat intake to reduce the incidence of these
potential side effects. These side effects may result in failure
of the plan. Fat-soluble vitamin absorption may be
decreased and require the use of fat-soluble vitamin supple-
mentation.51 Weight loss medications such as Meridia
(sibutramine), Redux(dexfenfluramine) and various pre-
scription or over-the-counter stimulants that do not act by
altering absorption have no specific nutritional supplement
considerations beyond those for any calorie-restricted diet.
Summary and Recommendations
Several points mentioned in this article bear repeating.
First, in regard to dietary weight-loss supplements, there is a
lack of strong evidence of efficacy or safety. None can be
recommended specifically for weight loss at this time
(SOR=C).35 However, incorporating nutritional supplements
as a part of a calorie-restriction-based weight-loss plan and
for post-bariatric surgery patients results in better nutritional
status and is advisable (SOR=B).34, 49
Finally, it is important to understand that the proper nutri-
tional approach to weight loss emphasizes good overall
nutritional practices, with the goal being a healthful diet;
the specific amount of weight lost through its implementa-
tion is secondary.
June 2010
Table 1. Additional Online Resources
General nutrition
Weight-loss supplements
1. Ogden CL, Carroll MD, Flegal KM. High body mass index for age among US children
and adolescents, 2003-2006. JAMA. May 28 2008;299(20):2401-2405.
2. Manson JE, Willett WC, Stampfer MJ, et al. Body weight and mortality among
women. N Engl J Med. Sep 14 1995;333(11):677-685.
3. Barbagallo CM, Cavera G, Sapienza M, et al. Prevalence of overweight and obesity
in a rural southern Italy population and relationships with total and cardiovascular
mortality: the Ventimiglia di Sicilia project. Int J Obes Relat Metab Disord.
Feb 2001;25(2):185-190.
4. Katzmarzyk PT, Craig CL, Bouchard C. Original article underweight, overweight and
obesity: relationships with mortality in the 13-year follow-up of the Canada Fitness
Survey. J Clin Epidemiol. Sep 2001;54(9):916-920.
5. Pi-Sunyer X, Kris-Etherton P. Improving health outcomes: future directions in the
field. J Am Diet Assoc. 2005;105( 5 Suppl 1):S14-S16.
6. Pillitteri JL, Shiffman S, Rohay JM, Harkins AM, Burton SL, Wadden TA. Use of
dietary supplements for weight loss in the United States: results of a national
survey. Obesity (Silver Spring). Apr 2008;16(4):790-796.
7. Blanck HM, Serdula MK, Gillespie C, et al. Use of nonprescription dietary
supplements for weight loss is common among Americans. J Am Diet Assoc.
Mar 2007;107(3):441-447.
Please note: Due to limited space, we are unable to list all references. You may
contact South Dakota Medicine at 605.336.1965 for a complete listing.
About the Authors:
Mark K. Huntington, MD, PhD, FAAFP, is Assistant Director, Sioux Falls Family Medicine
Residency Program, Center for Family Medicine, and Associate Professor, Department
of Family Medicine, Sanford School of Medicine at The University of South Dakota.
Roger A. Shewmake, PhD, LN, is Director of Nutrition, Sioux Falls Family Medicine
Residency Program, Center for Family Medicine; Co-chair, Society of Teachers of Family
Medicine Group on Nutrition; and Clinical Professor, Department of Family Medicine,
Sanford School of Medicine at The University of South Dakota.
... Increased obesity and overweight prevalence rates are also recorded in children aged below 5 years reaching 42 million in 2013 [1]. Treating obesity, however, has proven to be a complex endeavor that has been mostly unsuccessful [2,3], supporting its epidemic prevalence rates in children and adults [1,4,5]. Therefore, novel therapeutic strategies are warranted for preventing and/or combating this health threatening condition. ...
... If our hypothesis was to be confirmed, L-menthol-induced metabolic adaptations from WAT to BAT-like activity might provide a safe and efficient therapeutic agent for the development of novel strategies for obesity prevention and/or treatment. provide lasting benefits for health and wellbeing, often accompanied with serious side effects [2,3]. The recent discovery of functional BAT in human adults [33,34,51,69] has attracted much research attention as a therapeutic agent for treating obesity. ...
Introduction: Obesity constitutes a serious global health concern reaching pandemic prevalence rates. The existence of functional brown adipose tissue (BAT) in adult humans has provoked intense research interest in the role of this metabolically active tissue in whole-body energy balance and body weight regulation. A number of environmental, physiological, pathological, and pharmacological stimuli have been proposed to induce BAT-mediated thermogenesis and functional thermogenic BAT-like activity in white adipose tissue (WAT), opening new avenues for therapeutic strategies based on enhancing the number of beige adipocytes in WAT. Hypothesis: Recent evidence support a role of l-menthol cooling, mediated by TRPM8 receptor, on UCP1-dependent thermogenesis and BAT-like activity in classical WAT depots along with the recruitment of BAT at specific anatomical sites. l-Menthol-induced BAT thermogenesis has been suggested to occur by a β-adrenergic-independent mechanism, avoiding potential side-effects due to extensive β-adrenergic stimulation mediated by available beta receptor agonists. l-Menthol has been also linked to the activation of the cold-gated ion channel TRPA1. However, its role in l-menthol-induced UCP1-dependent thermogenic activity in BAT and WAT remains undetermined. White adipose tissue plasticity has important clinical implications for obesity prevention and/or treatment because higher levels of UCP1-dependent thermogenesis can lead to enhanced energy expenditure at a considerable extent. We hypothesize that chronic dietary l-menthol treatment could induce TRPM8- and TRPA1-dependent WAT adaptations, resembling BAT-like activity, and overall improve whole-body metabolic health in obese and overweight individuals. Conclusions: The putative impact of chronic l-menthol dietary treatment on the stimulation of BAT-like activity in classical WAT depots in humans remains unknown. A detailed experimental design has been proposed to investigate the hypothesized l-menthol-induced browning of WAT. If our hypothesis was to be confirmed, TRPM8/TRPA1-induced metabolic adaptations of WAT to BAT-like activity could provide a promising novel therapeutic approach for increasing energy expenditure, regulating body weight, and preventing obesity and its related co-morbidities in humans.
... Despite the growing cost of anti-CMD agents, there is concern that the drugs fail to provide lasting benefits for health and well-being (Huntington and Shewmake, 2010). In this light, identification of interethnic differences in UCP1 gene variants that could predispose certain ethnic groups to the development of CMDs could assist in the design of effective preventive and management practices, with beneficial outcomes for the public health care services. ...
Full-text available
Cardio-metabolic diseases (CMDs) comprise a cluster of risk factors that contribute to chronic pathological conditions with adverse consequences for cardiovascular function and metabolic processes. A wide range of CMD prevalence rates among different ethnic groups has been documented. In view of accumulated evidence, there is a trend toward increasing CMD prevalence rates in Eastern Europe and Western Asia. Numerous studies have revealed an association between uncoupling protein 1 (UCP1) gene variants and CMDs. UCP1 activity is essential for brown adipose tissue (BAT)-mediated thermogenesis. Experimental animal studies and epidemiological studies in humans highlight the significance of BAT-mediated thermogenesis in protecting against obesity and maintaining a lean phenotype. We hypothesize that the genetic variation in UCP1 gene expression observed among different ethnic groups could contribute to the ethnic-specific predisposition to CMD development. Constructing such prevalence maps of UCP1 gene variants could contribute significantly into identifying high-risk ethnic groups predisposed to the development of CMDs, and further shaping public health policies by the improvement of existing preventive and management strategies.
... Given (i) the medical and social impact of being overweight or obese, (ii) the few drugs marketed for these indications, and (iii) the safety concerns of these medications, more and more patients turn to weight-loss dietary supplements. However, none can be recommended specifically as there is a lack of strong evidence of efficacy or safety (Huntington and Shewmake, 2010). Adulteration of slimming dietary supplements is of a different nature from that of sexual enhancer supplements. ...
Nutritional supplements are products classified between medicines and conventional foods whose consumption is rising. The control of their quality is therefore of paramount importance in order to ensure their safety and to protect consumers. This chapter presents an overview on nutritional supplements considering three aspects. The first part is devoted to the complex problem of their definitions and regulations. The second part reviews the main chromatographic and spectroscopic techniques used to control the quality of the products. The third part deals with the major concern of intentional adulteration of dietary supplements with drugs or analogs. The poor quality of commercially available nutritional supplements is highlighted, thus emphasizing the need for stricter regulations and surveillance of a particularly complex market owing to the lack of clear and harmonized regulatory definitions and the fact that it easily defies control as a significant proportion of products is distributed via Internet.
Full-text available
We investigated the prevalence of overweight and obesity and their relationships with the main cardiovascular risk factors in the population of Ventimiglia di Sicilia, a rural village in Southern Italy characterized by low cholesterol levels and by a low incidence of early coronary heart disease mortality. We related all deaths to body weight and fat distribution during an 8 y follow-up. Cross-sectional and prospective observational study. A total of 835 free-living individuals, 363 males and 472 females, of age between 20 and 69 y. In all participants body weight, waist-to-hip ratio (WHR), cardiovascular risk factors and plasma lipids were measured. During the follow-up, total and cardiovascular deaths were registered. We found a high overall prevalence of subjects with overweight or obesity (respectively 45.0% and 27.7%), with great differences among classes of age. As expected, body weight and fat distribution were associated with diabetes, hypertension, dyslipidemia and with a worsening of lipid profile. During the follow-up we registered 37 total and 11 cardiovascular deaths. All-cause and cardiovascular mortality risks were, respectively, 1.64 (95% CI 0.65-4.15) and 2.71 (95% CI 0.29-25.26) in subjects with a body mass index (BMI) of 27-29.99 kg/m2 and 2.45 (95% CI 1.03-5.87) and 5.36 (95% CI 1.41-62.01) in subjects with a BMI of > or =30 kg/m2 in comparison with participants with a BMI of <27 kg/m2, and 3.48 (95% CI 1.46-8.30) and 4.55 (95% CI 1.12-18.40) in subjects with a WHR higher than the median in comparison with individuals with a WHR lower than the median. The Ventimiglia di Sicilia Study highlights the great importance of overweight and obesity as a public health issue in a rural population and indicates that it is necessary to consider the impact of body weight and fat distribution on both total and CHD mortality.
Full-text available
The prevalence of overweight among US children and adolescents increased between 1980 and 2004. To estimate the prevalence of 3 measures of high body mass index (BMI) for age (calculated as weight in kilograms divided by height in meters squared) and to examine recent trends for US children and adolescents using national data with measured heights and weights. Height and weight measurements were obtained from 8165 children and adolescents as part of the 2003-2004 and 2005-2006 National Health and Nutrition Examination Survey (NHANES), nationally representative surveys of the US civilian, noninstitutionalized population. Prevalence of BMI for age at or above the 97th percentile, at or above the 95th percentile, and at or above the 85th percentile of the 2000 sex-specific Centers for Disease Control and Prevention (CDC) BMI-for-age growth charts among US children by age, sex, and racial/ethnic group. Because no statistically significant differences in the prevalence of high BMI for age were found between estimates for 2003-2004 and 2005-2006, data for the 4 years were combined to provide more stable estimates for the most recent time period. Overall, in 2003-2006, 11.3% (95% confidence interval [CI], 9.7%-12.9%) of children and adolescents aged 2 through 19 years were at or above the 97th percentile of the 2000 BMI-for-age growth charts, 16.3% (95% CI, 14.5%-18.1%) were at or above the 95th percentile, and 31.9% (95% CI, 29.4%-34.4%) were at or above the 85th percentile. Prevalence estimates varied by age and by racial/ethnic group. Analyses of the trends in high BMI for age showed no statistically significant trend over the 4 time periods (1999-2000, 2001-2002, 2003-2004, and 2005-2006) for either boys or girls (P values between .07 and .41). The prevalence of high BMI for age among children and adolescents showed no significant changes between 2003-2004 and 2005-2006 and no significant trends between 1999 and 2006.
The relation between body weight and overall mortality remains controversial despite considerable investigation. We examined the association between body-mass index (defined as the weight in kilograms divided by the square of the height in meters) and both overall mortality and mortality from specific causes in a cohort of 115,195 U.S. women enrolled in the prospective Nurses' Health Study. These women were 30 to 55 years of age and free of known cardiovascular disease and cancer in 1976. During 16 years of follow-up, we documented 4726 deaths, of which 881 were from cardiovascular disease, 2586 from cancer, and 1259 from other causes. In analyses adjusted only for age, we observed a J-shaped relation between body-mass index and overall mortality. When women who had never smoked were examined separately, no increase in risk was observed among the leaner women, and a more direct relation between weight and mortality emerged (P for trend < 0.001). In multivariate analyses of women who had never smoked and had recently had stable weight, in which the first four years of follow-up were excluded, the relative risks of death from all causes for increasing categories of body-mass index were as follows: body-mass index < 19.0 (the reference category), relative risk = 1.0; 19.0 to 21.9, relative risk = 1.2; 22.0 to 24.9, relative risk = 1.2; 25.0 to 26.9, relative risk = 1.3; 27.0 to 28.9, relative risk = 1.6; 29.0 to 31.9, relative risk = 2.1; and > or = 32.0, relative risk = 2.2 (P for trend < 0.001). Among women with a body-mass index of 32.0 or higher who had never smoked, the relative risk of death from cardiovascular disease was 4.1 (95 percent confidence interval, 2.1 to 7.7), and that of death from cancer was 2.1 (95 percent confidence interval, 1.4 to 3.2), as compared with the risk among women with a body-mass index below 19.0. A weight gain of 10 kg (22 lb) or more since the age of 18 was associated with increased mortality in middle adulthood. Body weight and mortality from all causes were directly related among these middle-aged women. Lean women did not have excess mortality. The lowest mortality rate was observed among women who weighed at least 15 percent less than the U.S. average for women of similar age and among those whose weight had been stable since early adulthood.
The purpose of this study was to determine the risk of all-cause mortality in the Canadian population across the new WHO/NIH BMI categories for the classification of overweight and obesity. The sample includes 10,725 adult participants (20-69 years) in the 1981 Canada Fitness Survey. A total of 593 deaths occurred during 13 years of follow-up. Hazard ratios (HR) for mortality were estimated using Cox proportional hazards models. Compared to normal weight individuals, there is an increased risk of mortality in the underweight category (HR 1.63, 95% CI 0.93-2.85) in addition to increasing levels of risk across the overweight (HR 1.16, 95% CI 0.96-1.39), obese class I (HR 1.25, 95% CI 0.96-1.65) and obese class II and III (HR 2.96, 95% CI 1.39-6.29) categories. Similar patterns were observed in sex-specific analyses. Underweight, overweight and obese Canadians are all at increased risk of mortality compared to those who are normal weight.
Dietary supplements are not recommended as part of a weight-loss program due to concerns about efficacy and safety. This study sought to assess prevalence and duration of nonprescription weight-loss supplement use, associated weight-control behaviors, discussion of use with a health care professional, and specific ingredient use. Adults aged > or =18 years (n=9,403) completed a cross-sectional population-based telephone survey of health behaviors from September 2002 through December 2002. Both chi2 and t tests were conducted for categorical and mean comparisons and multiple variable logistic regression was used to determine significant predictors. An estimated 15.2% of adults (women 20.6%, men 9.7%) had ever used a weight-loss supplement and 8.7% had past year use (women 11.3%, men 6.0%); highest use was among women aged 18 to 34 years (16.7%). In regression models, use was equally prevalent among race/ethnic groups and education levels. One in 10 (10.2%) of users reported > or =12 month use, with less frequent long-term use in women (7.7%) than men (15.0%), P=0.01. Almost one third (30.2%) of users discussed use during the past year; 73.8% used a supplement containing a stimulant including ephedra, caffeine, and/or bitter orange. Use of supplements for losing weight seems to be common among many segments of the US adult population. Many adults are long-term users and most do not discuss this practice with their physician. Most of the weight-loss supplements taken contain stimulants. Qualified professionals should inquire about use of supplements for weight loss to facilitate discussion about the lack of efficacy data, possible adverse effects, as well as to dispel misinformation that may interfere with sound weight-management practices.
We examined dietary supplement use for weight loss and perceptions about safety, efficacy, and regulatory oversight of these products. A random digit-dialed telephone survey was conducted in 2005-2006, with a representative sample of 3,500 US adults. The survey assessed the beliefs and practices related to weight control. Outcome measures included the prevalence of dietary supplement use for weight reduction, demographic profile of supplement users, and knowledge about safety, efficacy, and regulation of dietary supplements. Of the adults who made a serious weight-loss attempt (n = 1,444), 33.9% reported ever using a dietary supplement for weight loss. Supplement use was more common among women (44.9%) vs. men (19.8%); those aged 25-34; African Americans (48.7%) or Hispanics (41.6%) vs. whites (31.2%); less educated (38.4% high school degree or less vs. 31.1% some college or more); lower income households (41.8% made <$40K vs. 30.3% made > or =$40K); obese (40.7%) vs. overweight (29.1%); those who made more lifetime weight-loss attempts (42.0% made > or =3 vs. 22.1% made <3); and those who used more weight-loss methods (48.2% used > or =4 vs. 25.2% used <4). Many users and non-users of dietary supplements had misperceptions about these products-many believed they are evaluated for safety and efficacy by the Food and Drug Administration (FDA) before marketing, and that dietary supplements are safer than over-the-counter (OTC) or prescription medications. Use of dietary supplements for weight loss is common. More information about dietary supplements is necessary to correct misperceptions and encourage the use of safe and effective weight-loss methods.
Sioux Falls Family Medicine Residency Program, Center for Family Medicine, and Associate Professor
  • K Mark
  • Huntington
  • Md
  • Faafp Phd
  • Assistant Is
  • Director
Mark K. Huntington, MD, PhD, FAAFP, is Assistant Director, Sioux Falls Family Medicine Residency Program, Center for Family Medicine, and Associate Professor, Department of Family Medicine, Sanford School of Medicine at The University of South Dakota.
PhD, LN, is Director of Nutrition, Sioux Falls Family Medicine Residency Program, Center for Family Medicine; Co-chair, Society of Teachers of Family Medicine Group on Nutrition; and Clinical Professor
  • Roger A Shewmake
Roger A. Shewmake, PhD, LN, is Director of Nutrition, Sioux Falls Family Medicine Residency Program, Center for Family Medicine; Co-chair, Society of Teachers of Family Medicine Group on Nutrition; and Clinical Professor, Department of Family Medicine, Sanford School of Medicine at The University of South Dakota.